Sanara MedTech Inc.

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanara MedTech (SMTI) reports record revenue in 2022, eyes market expansion

Sanara MedTech had a strong financial performance in 2022, despite increased expenses leading to a higher net loss. The company is strategically positioned to capitalize on opportunities in the Surgical Wound Care market and leverage partnerships for growth.

Sanara MedTech Inc. reports robust revenue growth and strategic advancements

Sanara MedTech Inc. demonstrated strong revenue growth and cost management in Q1 2023, with a focus on FDA clearances and product commercialization.
While facing supply challenges with Allocyte, the company's capital-raising efforts and strategic plans for BIASURGE offer promising opportunities for growth.
Overall, Sanara MedTech Inc. is positioned to capitalize on its product portfolio and partnerships to drive future success and market expansion.

Sanara MedTech reports robust Q2 growth amidst operational challenges

Sanara MedTech's Q2 2023 performance reflects strong revenue growth and improved financials, despite challenges like slower hiring and supply issues impacting sales.
The company's strategic strengths lie in innovation, market expansion efforts, and a proactive approach to addressing operational challenges for sustained growth.
Opportunities for Sanara MedTech include new product launches, international expansion, and strategic acquisitions to drive future revenue and market competitiveness.

Sanara MedTech (SMTI) posts record Q3 revenue, eyes growth opportunities

Sanara MedTech (SMTI) reported strong financial performance in Q3 with record revenues and improved margins, driven by strategic acquisitions and operational efficiencies.
While facing challenges like supply issues and increased expenses, the company is focused on leveraging new product launches and growth strategies for future success.
Opportunities lie in expanding market presence with innovative products, bundling strategies, and efficient operations to drive growth and enhance customer value.
Overall, Sanara MedTech's commitment to innovation, cost-effectiveness, and market expansion positions it well for long-term success and leadership in the healthcare industry.

Sanara MedTech Inc. reports record revenue, eyes growth through innovation

Sanara MedTech Inc. delivered strong revenue growth in 2023, driven by sales of soft tissue repair products.
While facing profitability challenges, the company's strategic focus on innovation and cost management bodes well for future growth.
Opportunities lie in expanding market presence, product offerings, and strategic partnerships to drive revenue and enhance competitiveness.
Efforts to improve outcomes in chronic wound care and lower costs demonstrate a commitment to long-term sustainability and market leadership.

Sanara MedTech (SMTI) reports record revenue and strategic growth initiatives

Sanara MedTech (SMTI) demonstrated strong financial performance in Q3 2024, with record revenue and positive EBITDA, driven by growth in soft tissue product sales.
Strategic investments in ChemoMouthpiece, LLC, and the upcoming launch of Tissue Health Plus (THP) position the company for future market disruption and revenue expansion.
While challenges exist in the Surgical segment's profitability, Sanara's overall performance and strategic initiatives present opportunities for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FORT WORTH, TX, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended June 30, 2022.

Sanara MedTech Inc. Announces Second Quarter 2022 Results

FORT WORTH, TX, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the second quarter ended June 30, 2022.

Sanara MedTech Inc. Announces Second Quarter 2022 Earnings Release and Conference Call Dates

FORT WORTH, TX, July 05, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it closed the acquisition of Scendia Biologics, LLC (“Scendia”) on July 1, 2022. Prior to this acquisition, Scendia was a sub-distributor of Sanara's and joint venture partner.

Sanara MedTech Inc. Announces Closing of Scendia Biologics, LLC Acquisition

Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2022 Earnings Conference Call May 17, 2022 9:00 AM ET Company Participants Callon Nichols - Director, Investor Relations Ron Nixon - Executive Chairman Zach Fleming - Chief Executive Officer Mike McNeil - Chief Financial Officer Conference Call Participants Ian Cassel - IFCM Operator Good morning, ladies and gentlemen, and welcome to the Sanara MedTech Inc. First Quarter 2022 Results and Business Update Conference Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.

Sanara MedTech Inc. (SMTI) CEO Zach Fleming on Q1 2022 Results - Earnings Call Transcript

FORT WORTH, TX , May 16, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended March 31, 2022.

Sanara MedTech Inc. Announces First Quarter 2022 Results

FORT WORTH, TX, May 02, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the first quarter ended March 31, 2022.

Sanara MedTech Inc. Announces First Quarter 2022 Earnings Release and Conference Call Dates

FORT WORTH, TX, April 04, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has closed the previously announced merger to acquire Precision Healing Inc.

Sanara MedTech Inc. Announces Closing of Merger to Acquire Precision Healing Inc.

FORT WORTH, TX, April 04, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has entered into a definitive agreement and plan of merger with Precision Healing Inc. (“Precision Healing”), pursuant to which Precision Healing will merge with and into a wholly owned subsidiary of Sanara. The transaction has been approved by the boards of directors of both companies, received the requisite approval of Precision Healing stockholders and is expected to close today, subject to satisfaction of customary closing conditions.

Sanara MedTech Inc. Announces Entry into Merger Agreement to Acquire Precision Healing Inc.

Sanara MedTech Inc. (SMTI) CEO Zach Fleming on Q4 2021 Results - Earnings Call Transcript

FORT WORTH, TX, March 30, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter and full year ended December 31, 2021.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Results

FORT WORTH, TX, March 14, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the fourth quarter and full year ended December 31, 2021.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Earnings Release and Conference Call Dates

FORT WORTH, TX , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today certain unaudited preliminary results for the fourth quarter and full year 2021.

Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2021

FORT WORTH, TX, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary (“Zach”) B. Fleming has been appointed Chief Executive Officer effective January 1, 2022.

Sanara MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer

FORT WORTH, TX , Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that J. Michael (“Mike”) Carmena will step down from the Company's Board of Directors (the “Board”) and resign as the Company's Principal Executive Officer, effective December 31, 2021 and Eric Tanzberger has been appointed to the Company's Board effective January 1, 2022. Concurrently with his appointment to the Board, Mr. Tanzberger was appointed Chair of the Audit Committee.

Sanara MedTech Inc. Announces the Retirement of J. Michael Carmena and Appointment of Eric Tanzberger to its Board of Directors

FORT WORTH, TX, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Roszell Mack III has been appointed to the Company's Board of Directors (the “Board”), effective January 1, 2022.

Sanara MedTech Inc. Announces the Appointment of Roszell Mack III to its Board of Directors

Sanara MedTech develops and sells medical products for post-surgery or chronic wounds. Their products are gaining traction, and revenue is growing rapidly (54.76% YoY revenue growth in the most recent quarter).

Sanara MedTech: Technology For Faster Healing Wounds

Sanara MedTech Inc. (SMTI) Management on Q3 2021 Results - Earnings Call Transcript

FORT WORTH, TX / ACCESSWIRE / November 12, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended September 30, 2021. Ron Nixon, Sanara's Executive Chairman, stated, "In the third quarter, Sanara continued to execute on its comprehensive wound and skin care strategy by gaining new hospital approvals for its surgical products, selling products into new facilities, executing an agreement and launching a pilot for WounDerm in the home health vertical, and adapting our EMR to the home health vertical.

Sanara MedTech Inc. Announces Third Quarter 2021 Results and Business Update

Sanara MedTech is undervalued based on the explosive growth in its primary product, Cellerate.

A Future Wound Care Compounder With Massive Upside Optionality - Sanara MedTech

FORT WORTH, TX / ACCESSWIRE / November 9, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced the commercial launch of two new innovative products from Cook Biotech Inc. Zach Fleming, Sanara's President, Surgical, stated, "A key component of our long-term strategy is to offer our customers more solutions that improve outcomes at a lower overall cost. The products that we are launching, in partnership with Cook Biotech, are innovative solutions for patients.

Sanara MedTech Inc. Announces the Commercial Launch of Two New Innovative Extracellular Matrix Products from Cook Biotech Inc.

FORT WORTH, TX / ACCESSWIRE / October 28, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the third quarter ended September 30, 2021. Sanara plans to issue its earnings release after the market closes on Friday, November 12, 2021, and will host a conference call on Monday, November 15, 2021, at 9:00 a.m.

Sanara MedTech Inc. Announces Third Quarter 2021 Earnings Release and Conference Call Dates

FORT WORTH, TX / ACCESSWIRE / September 22, 2021 / Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that the Company is scheduled to present virtually at the 2021 Cantor Virtual Global Healthcare Conference. Sanara's presentation will be given on Wednesday, September 29, 2021 at 9:20 a.m.

Sanara MedTech to Present at the 2021 Cantor Virtual Global Healthcare Conference

Sanara MedTech Inc. (SMTI) Management on Q2 2021 Results - Earnings Call Transcript

FORT WORTH, TX / ACCESSWIRE / August 16, 2021 / Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended June 30, 2021.

Sanara MedTech Inc. Announces Second Quarter 2021 Results and Business Update

FORT WORTH, TX / ACCESSWIRE / August 2, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today details for the release of its results for the second quarter ended June 30, 2021. Sanara plans to issue its earnings release after the market closes on Monday, August 16, 2021, and will host a conference call on Tuesday, August 17, 2021, at 9:00 a.m.

News for Sanara MedTech Inc. Stock (SMTI)